Q&A With Hayes Dansky From Janssen Pharmaceuticals: Using Xarelto to Treat Venous Thromboembolism In Everyday Practice
JANUARY 27, 2016
Venous thromboembolism (VTE) is a serious condition that requires a high level of care and treatment. A recent study looked at how the prescribing of Xarelto has helped the treatment process.
Hayes Dansky, MD, from Janssen Pharmaceuticals discussed the condition which affects almost 900,000 people in America every year during the annual meeting of the American Society of Hematology in Orlando. Dansky's presentation focused on the Xalia study which looked at how the medicationw as was being used in real world patient care and how effective it was in helping this patient population.
Related Coverage >>>
CD34+ Cell Therapy Receives Regenerative Medicine Advanced Therapy Designation by FDA for Refractory Angina